Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
-
BUSINESS Some 400 General Employees Likely Leaving Bayer under Redundancy Program
May 25, 2023
-
BUSINESS Lilly’s Omvoh Launch Set for June 21; BioMarin’s Palynziq Now Available
May 25, 2023
-
BUSINESS Novartis Japan Rolling Out New Operational Model Tailored to Local Needs: President
May 24, 2023
-
COMMENTARY Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
REGULATORY LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
-
REGULATORY Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
-
REGULATORY MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
-
BUSINESS Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
-
BUSINESS Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
-
ORGANIZATION Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
-
BUSINESS Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
-
BUSINESS Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
-
REGULATORY Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
-
REGULATORY Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
-
REGULATORY Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
-
REGULATORY Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
-
BUSINESS Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
May 17, 2023
-
BUSINESS Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
-
BUSINESS 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…